Evogene (EVGN) Misses Q1 EPS by 2c

Evogene (NASDAQ: EVGN) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $312 thousand versus the consensus estimate of $230.67 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Evogene to Present Its Pharma Division Achievements at the BIO International Convention
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c